Corporate information (Details)
kr / shares in Units, $ / shares in Units, € in Millions |
|
|
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
|
Jan. 01, 2029 |
Jan. 01, 2023 |
Jan. 01, 2021 |
Aug. 02, 2017
EUR (€)
|
Aug. 02, 2017
USD ($)
|
Nov. 30, 2017
USD ($)
|
Feb. 28, 2017
USD ($)
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2017
DKK (kr)
subsidiary
director
item
kr / shares
shares
|
Dec. 31, 2017
USD ($)
item
|
Dec. 31, 2017
USD ($)
subsidiary
director
item
shares
|
Aug. 02, 2017
kr / shares
|
Dec. 31, 2014
Vote
kr / shares
shares
|
Dec. 31, 2014
Vote
$ / shares
shares
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of subsidiaries | subsidiary |
|
|
|
|
|
|
|
|
2
|
|
2
|
|
|
|
| Initial capitalization, the Annual Funding and Sale expenses |
|
|
|
|
|
|
|
|
|
$ 759,000
|
|
|
|
|
| Share split ratio |
|
|
|
10
|
10
|
|
|
|
|
|
|
|
|
|
| Per share nominal value of an ordinary share | kr / shares |
|
|
|
|
|
|
|
|
kr 0.01
|
|
|
kr 0.01
|
kr 0.01
|
|
| Annulment of ordinary shares outstanding post share split (as a percent) |
|
|
|
80.00%
|
80.00%
|
80.00%
|
|
|
|
|
|
|
|
|
| Shareholder distribution (Capital Reduction) |
|
|
|
€ 917.7
|
$ 1,100,000,000
|
$ 32,200,000
|
|
|
|
$ 1,093,927,000
|
|
|
|
|
| Milligrams of DMF | item |
|
|
|
|
|
|
|
|
480
|
480
|
|
|
|
|
| Number of vote | Vote |
|
|
|
|
|
|
|
|
|
|
|
|
1
|
1
|
| ADS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of share per ADS | shares |
|
|
|
|
|
|
|
|
2
|
|
2
|
|
|
|
| IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds from issuance of shares |
|
|
|
|
|
|
|
$ 235,200,000
|
|
|
|
|
|
|
| Underwriting commission percentage |
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
| IPO | ADS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Per share nominal value of an ordinary share | (per share) |
|
|
|
|
|
|
|
|
|
|
|
|
kr 0.10
|
$ 21.00
|
| Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
11,200,000
|
11,200,000
|
| Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Duration of appeal process |
|
|
|
|
|
|
|
|
2 years
|
2 years
|
|
|
|
|
| Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Duration of appeal process |
|
|
|
|
|
|
|
|
3 years
|
3 years
|
|
|
|
|
| FWP IP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Capital commitments |
|
|
|
|
|
|
|
|
kr 100,000
|
|
$ 16,000
|
|
|
|
| Aditech |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Obligation payable |
|
|
|
|
|
|
|
|
|
|
$ 25,000,000
|
|
|
|
| Biogen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-refundable Fee |
|
|
|
|
|
|
$ 1,250,000,000
|
|
|
|
|
|
|
|
| Foundation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Group contribution as initial capitalization of the Foundation |
|
|
|
|
|
|
|
|
kr 5,000,000
|
$ 805,000
|
|
|
|
|
| Biogen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiaries who entered into an agreement | subsidiary |
|
|
|
|
|
|
|
|
2
|
|
2
|
|
|
|
| HoldCo | FWP IP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consideration for capital stock |
|
|
|
|
|
|
|
|
kr 336,000
|
|
$ 54,000
|
|
|
|
| Foundation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of board members | item |
|
|
|
|
|
|
|
|
3
|
|
3
|
|
|
|
| Number of independent directors | director |
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
| Number of directors | director |
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
| Foundation | Biogen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of directors | director |
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
| Co-exclusive license | Biogen | Interference Proceeding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of occasions license can be assigned to a single third party. | item |
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
| Forecast | Biogen | Opposition Proceeding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
20.00%
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Forecast | Co-exclusive license | Biogen | Interference Proceeding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
1.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forecast | Exclusive license | Biogen | Interference Proceeding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes To Consolidated Financial Statements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
20.00%
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|